Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia

被引:56
作者
Aitken, Samuel L. [1 ]
Altshuler, Jerry [2 ]
Guervil, David J. [2 ]
Hirsch, Elizabeth B. [1 ]
Ostrosky-Zeichner, Luis L. [3 ,4 ]
Ericsson, Charles D. [3 ,4 ]
Tam, Vincent H. [1 ]
机构
[1] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA
[2] Mem Hermann Texas Med Ctr, Dept Pharm, Houston, TX 77030 USA
[3] Mem Hermann Texas Med Ctr, Div Infect Dis, Houston, TX 77030 USA
[4] Univ Texas Hlth Sci Ctr Houston, Div Infect Dis, Houston, TX 77030 USA
关键词
Pharmacokinetics; Pharmacodynamics; Clinical outcomes; Pseudomonas; Acinetobacter; PHARMACODYNAMICS; ENTEROBACTERIACEAE; PHARMACOKINETICS; CEPHALOSPORINS; INFUSION;
D O I
10.1016/j.ijantimicag.2014.12.018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Cefepime is an antibiotic commonly used in nosocomial infections. The objective of this study was to elucidate the relationship between cefepime exposure and clinical outcome in patients with Gram-negative bacterial pneumonia. A previously published population pharmacokinetic model of cefepime was validated in 12 adult patients with normal renal function by measuring plasma concentrations at steady-state. Additionally, clinical outcomes for 33 patients with Gram-negative bacterial pneumonia who received cefepime monotherapy were determined. The free minimum concentration (fC(min)) to MIC ratio for each patient was determined by conditioning the validated pharmacokinetic model using patient-specific creatinine clearance (CLCr), dosing regimen and cefepime MIC of the organism isolated, and was subsequently correlated with clinical failure. Classification and regression tree (CART) analysis was used to determine the most significant drug exposure breakpoint. Mean +/- S.D. CLCr and cefepime C-min in the 12 patients were 87.5 +/- 21.2 mL/min and 6.2 +/- 3.8 mg/L, respectively. In comparison, the C-min predicted by the pharmacokinetic model was 5.8 mg/L using a CLCr. of 90 mL/min. MICs of organisms ranged from 0.5 mg/L to 8 mg/L. Percent time free drug above MIC of 100% was achieved in 32133 patients, but 12 patients experienced clinical failure. CART analysis determined patients with an fC(min)/MIC >= 2.1 had a significantly lower risk of clinical failure (OR = 0.11, 95% CI 0.02-0.67; P = 0.017). The fC(min)/MIC ratio is a useful predictor of clinical failure in Gram-negative bacterial pneumonia. The clinical utility of fC(min)/MIC in therapeutic drug monitoring should be further explored. (C) 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:541 / 544
页数:4
相关论文
共 15 条
[1]   Treatment of Extended-Spectrum Beta-Lactamase Enterobacteriaceae With Cefepime: The Dose Matters, Too [J].
Altshuler, Jerry ;
Aitken, Samuel L. ;
Guervil, David ;
Esaian, Diana ;
Papadopoulos, John ;
Arias, Cesar A. .
CLINICAL INFECTIOUS DISEASES, 2013, 57 (06) :915-916
[2]  
American Thoracic Society, AM J RESP CRIT CARE, V171, P388
[3]  
[Anonymous], J ANTIMICROB CHEMOTH
[4]  
[Anonymous], ANTIMICROB AGENTS CH
[5]  
[Anonymous], ANTIMICROB AGENTS CH
[6]  
[Anonymous], CLIN INFECT DIS
[7]   Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections [J].
Bauer, Karri A. ;
West, Jessica E. ;
O'Brien, James M. ;
Goff, Debra A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) :2907-2912
[8]   Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia [J].
Boselli, E ;
Breilh, D ;
Duflo, F ;
Saux, MC ;
Debon, R ;
Chassard, D ;
Allaouchiche, B .
CRITICAL CARE MEDICINE, 2003, 31 (08) :2102-2106
[9]   Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa [J].
Crandon, Jared L. ;
Bulik, Catharine C. ;
Kuti, Joseph L. ;
Nicolau, David P. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) :1111-1116
[10]   Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam [J].
Dudley, Michael N. ;
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Craig, William A. ;
Ferraro, Mary Jane ;
Jones, Ronald N. .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (09) :1301-1309